Richard Lanman

Richard Lanman (MD) is the Chief Medical Officer at Veracyte Inc. He joined Veracyte in 2008 as Chief Medical Officer. He previously served as Executive Vice President and Chief Medical Officer of diaDexus, Inc., where he drove commercialization of PLACTM, a molecular diagnostic test for heart attack and stroke risk. Dr. Lanman previously served as Executive Vice President of Corporate Development and Chief Medical Officer at Atherotech, an advanced cardiodiagnostics testing laboratory, where he lead clinical studies and business development. Prior to Atherotech, Dr. Lanman was Founder and CEO of Adesso, an application service provider profiling quality and utilization for specialist physician networks. Earlier in his career, he was in physician practice management roles as Senior Vice President and Medical Director for San Jose Medical Group, and as a Chief of Quality at Kaiser Permanente.